Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Aged ≥60 Years Treated with a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study (NCT02172872)Adriano Venditti, Francesco Buccisano, Anna Candoni et al.|Blood|2023Cited by 1
10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study groupMichael Lübbert, Gerwin Huls, Pierre W. Wijermans et al.|Blood|2025Cited by 1
Elevation of fetal hemoglobin is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC leukemia group, gimema and german MDS study groupJulia Stomper, Michael Lübbert, Michal Kiciński et al.|Blood|2025Cited by 0